drugset / Trial / NCT05807529
A Study to Evaluate the Safety and Efficacy of 2ccPA in Patients With Symptomatic Knee Osteoarthritis
RandomizedParallel-groupTriple-blindTreatment
Summary
This phase I/II study aims to evaluate the safety of single doses of 2ccPA 4,800 μg and 7,200 μg (Phase I), as well as the safety and efficacy of multiple doses of 2ccPA (Phase II) in patients with osteoarthritis (OA) of the knee.
Timeline
- Start
- 2022-11-03
- Primary completion
- 2024-12
- Completion
- 2024-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CARBACYCLIC PHOSPHATIDIC ACID | Small molecule | 2400 ug | — |
| Subject | CARBACYCLIC PHOSPHATIDIC ACID | Small molecule | 4800 ug | — |
| Subject | CARBACYCLIC PHOSPHATIDIC ACID | Small molecule | 7200 ug | — |